Mark Pollack to Placebos
This is a "connection" page, showing publications Mark Pollack has written about Placebos.
Connection Strength
0.784
-
Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov; 30(11):1114-20.
Score: 0.116
-
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
Score: 0.104
-
Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009 Nov; 70(11):1563-70.
Score: 0.088
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
Score: 0.079
-
The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.
Score: 0.067
-
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May; 62(5):350-7.
Score: 0.049
-
Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e206777.
Score: 0.046
-
Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998 Nov; 55(11):1010-6.
Score: 0.041
-
Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
Score: 0.036
-
Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord. 1994 Apr; 30(4):273-81.
Score: 0.030
-
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar; 63(3):298-304.
Score: 0.017
-
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
Score: 0.017
-
EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE ON SYSTOLIC BLOOD PRESSURE IN PSYCHIATRIC PATIENTS: RELATIONSHIPS TO AGE, DIAGNOSIS AND INITIAL BLOOD PRESSURE. J Psychiatr Res. 1964 Jan; 2:51-60.
Score: 0.015
-
Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003 May; 18(3):169-72.
Score: 0.014
-
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun; 157(6):968-74.
Score: 0.012
-
Is placebo response the same as drug response in panic disorder? Am J Psychiatry. 2000 Jun; 157(6):1014-6.
Score: 0.012
-
Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
Score: 0.011
-
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999 Mar; 174:213-8.
Score: 0.011
-
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 Nov; 155(11):1570-7.
Score: 0.010
-
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991 Feb; 52(2):69-76.
Score: 0.006
-
A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J Infect Dis. 1980 May; 141(5):543-7.
Score: 0.003